Age at time of treatment: 36 – 45
Injury Level: T6
Treatment Received: Stem Cells, Epidural Stimulation
Location of Treatment: Thailand
Time between injury and treatment: 5 – 15 years
Date of Surgery: 14/04/2018
Date of Discharge: 29/05/2018
Patient sustained a gunshot spinal cord injury at the T6 level in 1999. Patient’s MRI scan showed T6 fracture-dislocation with partial spinal cord transection and severe myelomalacia (softening of the spinal cord). Patient has minimal motor or sensory functions below the injury level and suffers from neurogenic bladder and bowel. Patient experiences some spasms and spasticity, but does not suffer from neuropathic pain. Patient is independent in his daily activities.
Patient has been receiving physiotherapy five times per week, one hour per session.
Patient sustained a gunshot spinal cord injury at the T6 level in 1999. Patient’s MRI scan showed T6 fracture-dislocation with partial spinal cord transection and severe myelomalacia (softening of the spinal cord). Patient has minimal motor or sensory functions below the injury level and suffers from neurogenic bladder and bowel. Patient experiences some spasms and spasticity, but does not suffer from neuropathic pain. Patient is independent in his daily activities.
After a spinal MRI scan, an EMG and comprehensive blood work, patient underwent laminectomy and implantation of the epidural stimulation device on April 14, 2018. The device is the ‘Medtronic Restore Advance 16-electrode MRI Compatible Device’. The surgery was completed without significant adverse events and no serious complications were reported during the postoperative hospital stay.
After Epidural Stimulation surgery, patient received 106 Mapping sessions and 39 physical therapy sessions. Patient also received 120 million Amniotic Fluid Stem Cells (hAFSCs): 40 million via one IV injection and 80 million via two lumbar puncture injections. All three applications went well without adverse effects and no short-term or acute complications have been reported.
Device mapping and therapy were carried out after surgery for 35 days, then patient was discharged.
Improvements are monitored in 15 targeted areas: 11 Motor areas and 4 Sensory areas. However, the number of targeted areas may vary depending on patient’s condition prior to admission. If patient does not experience symptoms in certain Motor/Sensory functions, or is not impaired in a specific targeted area prior to surgery, it is excluded from the report (Not Applicable). If there is progress in any given area — either mild, moderate, or significant — it is measured and reported as positive (“Yes”). No improvement, the existence of pain or spasms, or an inability to perform a measured function is reported as “No”.
Patient is paraplegic and has normal upper body functions. Therefore fine motor skills were excluded from this report. Motor function improved in 10 out of the 10 targeted areas when the epidural stimulation device was switched on.
Patient does not suffer from neuropathic pain therefore in this case it is considered “not applicable”. Patient has not experienced any improvements in the other sensory function areas, but more feedback will be collected after 3 months to note any improvements made by stem cell treatment. Overall, improvements were recorded in 10 out of 13 targeted motor and sensory function areas.
epiduralstimulationnow.com is owned by Verita Neuro Pte. Ltd. Verita Neuro provides access to progressive, responsible healthcare to increase the quality of life. Verita Neuro partners with leading-edge, next-generation treatment providers, unique products and services, that are integrative, safe and effective. Verita Neuro is not a treatment provider.
All medical treatments have varied outcomes. Results from the treatments will vary from patient to patient. All examples of what has been achieved by others should not be taken as typical or in any way a guarantee or projection of what any individual can expect from treatment.